These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31375661)

  • 1. A genome-wide positioning systems network algorithm for in silico drug repurposing.
    Cheng F; Lu W; Liu C; Fang J; Hou Y; Handy DE; Wang R; Zhao Y; Yang Y; Huang J; Hill DE; Vidal M; Eng C; Loscalzo J
    Nat Commun; 2019 Aug; 10(1):3476. PubMed ID: 31375661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MNBDR: A Module Network Based Method for Drug Repositioning.
    Chen HG; Zhou XH
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
    Das AB
    BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19.
    Rivero-García I; Castresana-Aguirre M; Guglielmo L; Guala D; Sonnhammer ELL
    Sci Rep; 2021 Oct; 11(1):20687. PubMed ID: 34667255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network controllability solutions for computational drug repurposing using genetic algorithms.
    Popescu VB; Kanhaiya K; Năstac DI; Czeizler E; Petre I
    Sci Rep; 2022 Jan; 12(1):1437. PubMed ID: 35082323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
    Fiscon G; Conte F; Farina L; Paci P
    PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network medicine framework for identifying drug-repurposing opportunities for COVID-19.
    Morselli Gysi D; do Valle Í; Zitnik M; Ameli A; Gan X; Varol O; Ghiassian SD; Patten JJ; Davey RA; Loscalzo J; Barabási AL
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33906951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma.
    Hu W; Wang G; Chen Y; Yarmus LB; Liu B; Wan Y
    Aging (Albany NY); 2020 Aug; 12(16):16514-16538. PubMed ID: 32855362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug Repurposing.
    Martinez-Hernandez JE; Hammoud Z; de Sousa AM; Kramer F; Monte-Neto RLD; Maracaja-Coutinho V; Martin AJM
    Microbiol Spectr; 2021 Oct; 9(2):e0101821. PubMed ID: 34668739
    [No Abstract]   [Full Text] [Related]  

  • 10. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
    Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
    Zador Z; King AT; Geifman N
    PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β‑elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A‑VEGFA pathway based on network pharmacology.
    Zhu J; Li B; Ji Y; Zhu L; Zhu Y; Zhao H
    Oncol Rep; 2019 Dec; 42(6):2561-2571. PubMed ID: 31638231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of key regulators responsible for dysregulated networks in osteoarthritis by large-scale expression analysis.
    Shi S; Wan F; Zhou Z; Tao R; Lu Y; Zhou M; Liu F; Liu Y
    J Orthop Surg Res; 2021 Apr; 16(1):259. PubMed ID: 33853636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks.
    Liu H; Song Y; Guan J; Luo L; Zhuang Z
    BMC Bioinformatics; 2016 Dec; 17(Suppl 17):539. PubMed ID: 28155639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network-based approach to prediction and population-based validation of in silico drug repurposing.
    Cheng F; Desai RJ; Handy DE; Wang R; Schneeweiss S; Barabási AL; Loscalzo J
    Nat Commun; 2018 Jul; 9(1):2691. PubMed ID: 30002366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinoma.
    Graves OK; Kim W; Özcan M; Ashraf S; Turkez H; Yuan M; Zhang C; Mardinoglu A; Li X
    Biomed Pharmacother; 2023 May; 161():114486. PubMed ID: 36906970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic integration of biomedical knowledge prioritizes drugs for repurposing.
    Himmelstein DS; Lizee A; Hessler C; Brueggeman L; Chen SL; Hadley D; Green A; Khankhanian P; Baranzini SE
    Elife; 2017 Sep; 6():. PubMed ID: 28936969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
    De Bastiani MA; Klamt F
    Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Drug Treatment Patterns Based on the Action of Drug and Multilayer Network Model.
    Yu L; Shi Y; Zou Q; Wang S; Zheng L; Gao L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.